Table 5.
Ingenuity Canonical Signaling Pathway analysis of proteins differentially regulated in the cortex of aged BTBR compared to WT controls.
| Canonical pathways | log(p-value) | Ratio | 10 × Hybrid |
|---|---|---|---|
| Leptin Signaling in Obesity | 3.97E + 00 | 4.71E–02 | 1.86987 |
| Role of JAK family kinases in IL-6-type Cytokine Signaling | 2.52E + 00 | 7.14E–02 | 1.79928 |
| Amyloid Processing | 3.20E + 00 | 4.92E–02 | 1.5744 |
| Melanocyte Development and Pigmentation Signaling | 3.73E + 00 | 4.21E–02 | 1.57033 |
| Gαi Signaling | 3.16E + 00 | 2.96E–02 | 0.93536 |
| Dopamine Receptor Signaling | 2.70E + 00 | 3.12E–02 | 0.8424 |
| CDK5 Signaling | 2.52E + 00 | 3.09E–02 | 0.77868 |
| α-Adrenergic Signaling | 2.52E + 00 | 2.75E–02 | 0.693 |
| IGF-1 Signaling | 2.40E + 00 | 2.80E–02 | 0.672 |
| CNTF Signaling | 1.90E + 00 | 3.51E–02 | 0.6669 |
| Neuropathic Pain Signaling In Dorsal Horn Neurons | 2.36E + 00 | 2.75E–02 | 0.649 |
| G Beta Gamma Signaling | 2.50E + 00 | 2.48E–02 | 0.62 |
| IL-2 Signaling | 1.88E + 00 | 3.28E–02 | 0.61664 |
| Thrombopoietin Signaling | 1.85E + 00 | 3.12E–02 | 0.5772 |
| Renin-Angiotensin Signaling | 2.26E + 00 | 2.38E–02 | 0.53788 |
| Gαs Signaling | 2.22E + 00 | 2.40E–02 | 0.5328 |
| Role of JAK1 and JAK3 in γc Cytokine Signaling | 1.75E + 00 | 2.94E–02 | 0.5145 |
| GM-CSF Signaling | 1.74E + 00 | 2.94E–02 | 0.51156 |
| Clathrin-mediated Endocytosis Signaling | 2.49E + 00 | 2.02E–02 | 0.50298 |
| Regulation of Cellular Mechanics by Calpain Protease | 1.82E + 00 | 2.74E–02 | 0.49868 |
| CREB Signaling in Neurons | 2.58E + 00 | 1.93E–02 | 0.49794 |
| Glutamate Receptor Signaling | 1.79E + 00 | 2.78E–02 | 0.49762 |
| Synaptic Long Term Potentiation | 2.14E + 00 | 2.31E–02 | 0.49434 |
| Antiproliferative Role of Somatostatin Receptor 2 | 1.73E + 00 | 2.78E–02 | 0.48094 |
| Agrin Interactions at Neuromuscular Junction | 1.68E + 00 | 2.86E–02 | 0.48048 |
| JAK/Stat Signaling | 1.69E + 00 | 2.82E–02 | 0.47658 |
| Corticotropin Releasing Hormone Signaling | 2.21E + 00 | 2.07E–02 | 0.45747 |
| Neurotrophin/TRK Signaling | 1.68E + 00 | 2.63E–02 | 0.44184 |
| P2Y Purigenic Receptor Signaling Pathway | 2.12E + 00 | 2.08E–02 | 0.44096 |
| Renal Cell Carcinoma Signaling | 1.65E + 00 | 2.53E–02 | 0.41745 |
| Insulin Receptor Signaling | 2.03E + 00 | 2.01E–02 | 0.40803 |
| Melatonin Signaling | 1.65E + 00 | 2.47E–02 | 0.40755 |
| FLT3 Signaling in Hematopoietic Progenitor Cells | 1.60E + 00 | 2.53E–02 | 0.4048 |
| GNRH Signaling | 2.05E + 00 | 1.96E–02 | 0.4018 |
| cAMP-mediated signaling | 2.23E + 00 | 1.77E–02 | 0.39471 |
| Ephrin B Signaling | 1.61E + 00 | 2.44E–02 | 0.39284 |
| Prolactin Signaling | 1.62E + 00 | 2.38E–02 | 0.38556 |
| BMP signaling pathway | 1.59E + 00 | 2.33E–02 | 0.37047 |
| Relaxin Signaling | 1.98E + 00 | 1.83E–02 | 0.36234 |
| FGF Signaling | 1.49E + 00 | 2.13E–02 | 0.31737 |
| Gap Junction Signaling | 1.83E + 00 | 1.66E–02 | 0.30378 |
| Apoptosis Signaling | 1.47E + 00 | 2.00E–02 | 0.294 |
| Acute Phase Response Signaling | 1.74E + 00 | 1.66E–02 | 0.28884 |
| G-Protein Coupled Receptor Signaling | 1.99E + 00 | 1.45E–02 | 0.28855 |
| Mouse Embryonic Stem Cell Pluripotency | 1.41E + 00 | 2.02E–02 | 0.28482 |
| Neuregulin Signaling | 1.47E + 00 | 1.92E–02 | 0.28224 |
| FAK Signaling | 1.48E + 00 | 1.89E–02 | 0.27972 |
| Chronic Myeloid Leukemia Signaling | 1.42E + 00 | 1.89E–02 | 0.26838 |
| VEGF Signaling | 1.43E + 00 | 1.83E–02 | 0.26169 |
| IL-1 Signaling | 1.42E + 00 | 1.83E–02 | 0.25986 |
| Sertoli Cell-Sertoli Cell Junction Signaling | 1.69E + 00 | 1.52E–02 | 0.25688 |
| PPARα/RXRα Activation | 1.69E + 00 | 1.50E–02 | 0.2535 |
| HGF Signaling | 1.37E + 00 | 1.80E–02 | 0.2466 |
| Mitochondrial Dysfunction | 1.76E + 00 | 1.40E–02 | 0.2464 |
| Ephrin Receptor Signaling | 1.70E + 00 | 1.43E–02 | 0.2431 |
| Role of NFAT in Cardiac Hypertrophy | 1.66E + 00 | 1.44E–02 | 0.23904 |
| Calcium Signaling | 1.67E + 00 | 1.38E–02 | 0.23046 |
| Integrin Signaling | 1.57E + 00 | 1.44E-02 | 0.22608 |
| Leukocyte Extravasation Signaling | 1.56E + 00 | 1.43E-02 | 0.22308 |
| Breast Cancer Regulation by Stathmin1 | 1.59E + 00 | 1.40E–02 | 0.2226 |
| Fc Epsilon RI Signaling | 1.30E + 00 | 1.71E–02 | 0.2223 |
| Nitric Oxide Signaling in the Cardiovascular System | 1.36E + 00 | 1.60E–02 | 0.2176 |
| NGF Signaling | 1.32E + 00 | 1.64E–02 | 0.21648 |
| Axonal Guidance Signaling | 1.86E + 00 | 1.03E–02 | 0.19158 |
| Cardiac Hypertrophy Signaling | 1.42E + 00 | 1.20E–02 | 0.1704 |
| Molecular Mechanisms of Cancer | 1.58E + 00 | 1.03E–02 | 0.16274 |
| Colorectal Cancer Metastasis Signaling | 1.34E + 00 | 1.12E–02 | 0.15008 |
| Protein Kinase A Signaling | 1.43E + 00 | 9.78E–03 | 0.139854 |
Canonical signaling pathway annotation of the cortical proteins possessing BTBR:WT iTRAQ expression ratios <1.2 or <0.8 was created using Ingenuity Pathway Analysis. Each signaling pathway significantly populated (p < 0.05) by at least two independent proteins are depicted. For each populated signaling pathway the −log10 of the enrichment probability (p-value), the enrichment ratio and the calculated hybrid score [10 * (enrichment ratio * −log10(p-value))] are depicted.